Intas launches DoceAqualip in India

30 September 2014

Indian drugmaker Intas Pharmaceuticals says it has successfully launched the world’s first DoceAqualip with nanosomal docetaxel lipid suspension (NDLS) formula, in India.

DoceAqualip, created with Nano Aqualip Technology has Nano-carriers in suspension form composed of physiological (GRAS- generally recognized as safe) lipid excipients which causes negligible hypersensitivity after administration of drugs among the cancer patients.

DoceAqualip has been approved by Director Controller General of India (DCGI) on the basis of clinical trial in which DoceAqualip offered 9% better response rates than conventional docetaxel. In three-year interim survival analysis, DoceAqualip showed better results than conventional docetaxel. It is approved in breast cancer, hormone refractory prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of the head and neck (SCCHN).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK